Immutep Limited (IMMP) Price-to-Projected Revenue Ratio

Corporate company logo of Immutep Ltd (IMMP)

Immutep Limited business depends on global logistics and the stability of supplies from Asia. The company relies on developments in Europe and Australia to create LAG-3 protein-based immunotherapy. Active R&D processes are currently focused on releasing data regarding the treatment of lung and breast cancer. The current value is 2.70, and the GURU.Markets system displays this chart of the projected P/S dynamics.

IMMP Immutep Ltd: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Immutep Corp (IMMP)

- current price and projected stock value:
Stock Price Immutep|IMMP - Analyst Median Target
- market capitalization details:
Market Value Immutep Corp|IMMP - Real Price to Acquire Entire Company
- book value of equity indicators:
Net Assets per Single Share Immutep|IMMP - Company Net Assets|Market Cap to Net Assets Ratio immutep.com|IMMP - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio Immutep Limited|IMMP - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Immutep Limited|IMMP - Company Cumulative Debt|Debt to Book Capitalization Ratio Immutep Corp|IMMP - Long-Term Liabilities|Company Current Liabilities Immutep|Quick Liquidity immutep.com
- business earnings and investment ratios data:
IMMP - Company Net Income|Projected Future Earnings Immutep Limited|IMMP - Business Payback Period|Future Price to Earnings Immutep Limited ADR|IMMP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Immutep Corp|IMMP - Operating income before deduction of amortization|Net earnings per share for the last 12 months Immutep|IMMP - Earnings per share for the last four quarters|Quarterly EPS earnings growth immutep.com|IMMP - Earnings per share growth rate in current year|Earnings growth forecast for next year Immutep Limited
- sales and revenue data:
IMMP - Company Sales Volume|Projected Sales Volume Immutep|IMMP - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Immutep Corp
Initial company analysis:IMMP (Immutep)
Manufactured products of Immutep Corp

For Immutep Limited (IMMP), a developer of advanced LAG-3 immunotherapy for oncology, the firm's forward P/S ratio serves as an indicator of market expectations regarding the future commercialization of its developments. This ratio correlates current market capitalization with projected revenue, reflecting the dynamics of risk reassessment and business growth potential, which necessitates caution during sharp spikes on the chart to avoid correction losses.

Direct competitors

Forward P/S Multiple MRUS (Merus)|Market Cap to Expected Sales Ratio Anixa Biosciences (ANIX)|ATOS - Price-to-Projected Revenue Ratio|Context Therapeutics (CNTX) - Forward Price-to-Revenue Multiple|mersana.com (MRSN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple briacell.com|Forward Price-to-Revenue Multiple EPIX|Forward P/S Multiple QT Imaging Holdings